Inozyme Pharma Inc
General ticker "INZY" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $176.8M
Inozyme Pharma Inc does not follow the US Stock Market performance with the rate: -3.9%.
Estimated limits based on current volatility of 5.2%: low 2.73$, high 3.03$
Factors to consider:
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [2.47$, 7.09$]
- 2024-12-30 to 2025-12-30 estimated range: [2.24$, 6.39$]
Financial Metrics affecting the INZY estimates:
- Negative: Non-GAAP EPS, $ of -1.39 <= 0.10
- Negative: Operating profit margin, % of -100 <= 1.03
- Negative: negative Net income
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
- Negative: Industry earnings per price (median), % of -26.04 <= 1.31
- Positive: -3.48 < Investing cash flow per share, $ of -1.03
- Negative: Operating cash flow per share per price, % of -25.70 <= 2.35
- Negative: 0 < Interest expense per share, $ of 0.06
- Negative: Industry operating profit margin (median), % of -98.30 <= 2.14
Short-term INZY quotes
Long-term INZY plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $56.65MM | $68.67MM | $75.64MM |
| Operating Income | $-56.65MM | $-68.67MM | $-75.64MM |
| Non-Operating Income | $0.02MM | $1.42MM | $4.48MM |
| Interest Expense | $0.00MM | $0.00MM | $3.33MM |
| R&D Expense | $37.72MM | $47.85MM | $54.85MM |
| Income(Loss) | $-56.63MM | $-67.26MM | $-71.17MM |
| Profit(Loss) | $-56.63MM | $-67.26MM | $-71.17MM |
| Stockholders Equity | $109.27MM | $118.39MM | $140.48MM |
| Inventory | $0.06MM | $0.12MM | $0.00MM |
| Assets | $123.54MM | $139.19MM | $200.85MM |
| Operating Cash Flow | $-48.15MM | $-57.76MM | $-70.67MM |
| Capital expenditure | $0.40MM | $0.41MM | $0.30MM |
| Investing Cash Flow | $42.80MM | $-5.40MM | $-53.65MM |
| Financing Cash Flow | $0.61MM | $72.79MM | $125.97MM |
| Earnings Per Share* | $-2.39 | $-1.73 | $-1.37 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.